Product Information

EQUETRO 300 MG CAPSULE is a brand product labeled by Validus Pharmaceuticals LLC, priced at $4.7053 per EA under NDC 30698042312. Its NADAC has been published 248 times since Nov 28, 2013.

FDA first approved this application on Dec 10, 2004.

The High Outlier badge above means this manufacturer's average price in the Carbamazepine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

EQUETRO 300 MG CAPSULE

Carbamazepine
$4.7053per EA
High Outlier

Strength

300 mg/1

NDC

30698042312

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

CARBAMAZEPINE

Approval Type

New Drug (NDA)

FDA Application

NDA021710

FDA Approved

12/10/2004

On Market Since

12/10/2004

Pharmacological Classes

Cytochrome P450 1A2 Inducers
Cytochrome P450 2B6 Inducers
Cytochrome P450 2C19 Inducers
Cytochrome P450 2C9 Inducers
Cytochrome P450 3A4 Inducers
Decreased Central Nervous System Disorganized Electrical Activity
Mood Stabilizer

Price Statistics

The NADAC for EQUETRO 300 MG CAPSULE has been published 248 times since Nov 28, 2013, and over the history we have for it it has risen 102.8%. The table below summarizes its recorded NADAC range and movement.

Current price$4.7053 per EA
All-time high$4.7197 (Jul 10, 2024)
All-time low$2.3199 (Nov 28, 2013)
52-week high$4.7053
52-week low$4.6670
Median price$3.3758
Average price$3.8980
Largest weekly change+40.0% (May 21, 2014)
Weeks tracked248
Tracking sinceNov 28, 2013

Price History

1W

+0.0%

1M

+0.0%

3M

+0.1%

6M

+0.1%

1Y

+0.8%

3Y

+39.4%

5Y

+39.4%

All

+102.8%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 79% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of EQUETRO 300 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for EQUETRO 300 MG CAPSULE, manufactured by Validus Pharmaceuticals LLC, is $4.7053 per EA (NDC 30698042312), effective Aug 19, 2026.

How has the price of EQUETRO 300 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for EQUETRO 300 MG CAPSULE has risen 102.8%. It has been tracked across 248 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for EQUETRO 300 MG CAPSULE?

Since Nov 28, 2013, the NADAC for EQUETRO 300 MG CAPSULE has ranged from a low of $2.3199 (Nov 28, 2013) to a high of $4.7197 (Jul 10, 2024), with a median of $3.3758 per EA.

Are there cheaper alternatives to EQUETRO 300 MG CAPSULE?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBAMAZEPINE ER 300 MG CAP, is $1.0113 per EA — about 79% below EQUETRO 300 MG CAPSULE.

Who manufactures EQUETRO 300 MG CAPSULE?

EQUETRO 300 MG CAPSULE (NDC 30698042312) is labeled by Validus Pharmaceuticals LLC, and CMS classifies it as a brand product.